Microarrays have been widely used for the analysis of gene expression and several commercial platforms are available. The combined use of multiple platforms can overcome the inherent biases of each approach, and may represent an alternative that is complementary to RT-PCR for identification of the more robust changes in gene expression profiles.
Cross platform microarray analysis for robust identification of differentially expressed genes.
No sample metadata fields
View SamplesTreatment with Aurora inhibitors has been shown to induce diverse biological responses in different tumor cell lines, in part depending on their p53 status. To characterize at the transcriptional level the effects of Danusertib we analyzed by microarray different tumor cell lines, with WT or mutant p53 status, that showed differential cell cycle response upon drug treatment.
Transcriptional analysis of the Aurora inhibitor Danusertib leading to biomarker identification in TP53 wild type cells.
Specimen part, Cell line
View SamplesThis SuperSeries is composed of the SubSeries listed below.
Discovery of drug mode of action and drug repositioning from transcriptional responses.
Specimen part, Cell line, Treatment
View SamplesThe effects of several compounds on the MCF7 human adenocarcinoma mammary cell line were analysed by gene expression profiling.
Discovery of drug mode of action and drug repositioning from transcriptional responses.
Specimen part, Cell line, Treatment
View SamplesThe effects of the CDK inhibitors PHA-848125 and PHA-690509 on the A2780 cell line were analysed by gene expression profiling.
Discovery of drug mode of action and drug repositioning from transcriptional responses.
Specimen part, Cell line, Treatment
View SamplesThe effects of the CDK inhibitor PHA-793887 on the A2780 human adenocarcinoma ovary cell line were analysed by gene expression profiling.
Discovery of drug mode of action and drug repositioning from transcriptional responses.
Specimen part, Cell line, Treatment
View SamplesThe effects of the CDK inhibitor PHA-848125 (referred to as CDK-125) on the MCF7 human adenocarcinoma mammary cell line were analysed by gene expression profiling.
Discovery of drug mode of action and drug repositioning from transcriptional responses.
Specimen part, Cell line, Treatment
View SamplesThe effects of the CDK inhibitor Flavopiridol on the A2780 human adenocarcinoma ovary cell line were analysed by gene expression profiling.
Discovery of drug mode of action and drug repositioning from transcriptional responses.
Specimen part, Cell line, Treatment
View SamplesFNDC4 is a novel secreted factor sharing high homology with the exercise-associated myokine irisin (FNDC5). Here we report that Fndc4 is robustly upregulated in various mouse models of inflammation as well as in human inflammatory conditions. Specifically, subjects with inflammatory bowel disease show increased FNDC4 levels locally at inflamed sites of the intestine. Interestingly, administration of recombinant FNDC4 during colitis development in mice resulted in markedly reduced disease severity compared to mice injected with a control protein. Conversely, mice that lacked Fndc4 showed increased colitis severity. Analysis of binding of FNDC4 to different immune cell types revealed strong and specific binding to macrophages and monocytes. FNDC4 treatment of bone marrow-derived macrophages in vitro resulted in reduced phagocytosis, improved survival and reduced pro-inflammatory chemokine expression. Hence, treatment with FNDC4 resulted in a state of dampened macrophage activity, while enhancing their survival. Thus, we have characterized a novel factor with direct therapeutic potential in inflammatory bowel disease and possibly other inflammatory diseases.
FNDC4 acts as an anti-inflammatory factor on macrophages and improves colitis in mice.
Sex, Specimen part, Treatment
View SamplesBackground: The selective absorption of nutrients and other food constituents in the small intestine is mediated by a group of transport proteins and metabolic enzymes, often collectively called intestinal barrier proteins. An important receptor that mediates the effects of dietary lipids on gene expression is the peroxisome proliferator-activated receptor alpha (PPAR), which is abundantly expressed in enterocytes. In this study we examined the effects of acute nutritional activation of PPAR on expression of genes encoding intestinal barrier proteins. To this end we used triacylglycerols composed of identical fatty acids in combination with gene expression profiling in wild-type and PPAR-null mice. Treatment with the synthetic PPAR agonist WY14643 served as reference.
PPARalpha-mediated effects of dietary lipids on intestinal barrier gene expression.
No sample metadata fields
View Samples